期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

克唑替尼治疗EML4-ALK重排阳性患者的临床疗效 被引量：10

Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer
下载PDF
导出
摘要 目的探讨EML4-ALK融合基因阳性与阴性非小细胞肺癌患者在应用不同治疗方案后的临床疗效。方法对有自主意愿进行EML4-ALK基因检测的21例ALK阳性、50例ALK阴性与75例未行ALK检测的非小细胞肺癌患者,对3组患者给予不同的治疗方法,并对疗效、无疾病生存期及不良反应做出统计学分析。结果对于EML4-ALK阳性患者,应用克唑替尼后的PFS明显延长,其客观缓解率为61.9%,明显高于应用化疗药物之后的客观缓解率。对比与EML4-ALK阴性及未测组的二线治疗方案,其客观缓解率及疾病控制率也有显著统计学差异。结论克唑替尼对EML4-ALK阳性患者具有更好的疗效,EML4-ALK基因重排与否对化疗药物并无影响。 Objective To evaluate the therapeutic effects of different therapeutic regimens for non-small-cell lung cancer （NSCLC） with or without EML4-ALK rearrangement. Methods Twenty-one ALK-positive and 50 ALK-negative NSCLC patients who received voluntarily EML4-ALK testing and 75 NSCLC patients without AL testing were enrolled in this study. The 3 groups of patients received different treatments, and the therapeutic effects, progression-free survival （PFS）, and treatment-related adverse events were analyzed. Result Crizotinib treatment obviously prolonged the PFS in EML4-ALK-positive patients with an objective response rate （OOR） of 61.9%and a median response duration of 16 months, which were significantly better than those in with ALK-negative patients and patients without ALK testing who received different second-line therapies. Conclusion Crizotinib is superior to platinum- based chemotherapy in NSCLC patients with ALK rearrangement. ALK rearrangement id not a modifier of the effect of chemotherapy regimens in NSCLC patients.
作者 吴璇 李建雄
机构地区 中国人民解放军总医院放射治疗科
出处 《南方医科大学学报》 CAS CSCD 北大核心 2015年第5期753-757,共5页 Journal of Southern Medical University
基金 国家自然科学基金(81001042) 北京市科技新星交叉项目(Z141107001814122)~~
关键词 非小细胞肺癌 克唑替尼 EML4-ALK重排 化疗 non-small cell lung carcinoma crizotinib ALK-rearrangement chemotherapy
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献26

  • 1Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter[J]. J Clin Oncol, 2013, 31(8): 1112-21.
  • 2Jang SH, Long T. Therapeutic plan for patients with Non-Small cell lung Cancer harboring EGFR mutation E J]. Tuberc Respir Dis (Seoul), 2014, 76(8): 8-14.
  • 3杨彦卓,潘乐康,安广宇.非小细胞肺癌中EML4-ALK融合基因的生物学特性及其治疗[J].肿瘤,2012,32(6):466-470. 被引量：6
  • 4Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma Kinase-Rearranged Non-Small cell lung cancer[J]. Clin Pharmacol Ther, 2014, 95 (1): 15-23.
  • 5Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases[J]. Blood, 2003, 102(7): 2568-73.
  • 6Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors[J]. Am J Pathol, 2000, 157(2): 377-84.
  • 7Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448(7153): 561-6.
  • 8Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers[J]. Mol Cancer Res, 2009, 7(9): 1466-76.
  • 9Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients [J]. Mod Pathol, 2012, 25(11): 1516-25.
  • 10Chen YY, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma[J]. Nature, 2008, 455(7215): U56-971.

二级参考文献32

  • 1夏曙,于世英.PI3K/Akt信号转导通路在恶性肿瘤中的研究进展[J].肿瘤,2006,26(6):576-578. 被引量：29
  • 2SODA M, CHOI Y L, ENOMOTO M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.
  • 3KWAK E L, CAMIDGE D R, CLARK J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066[J].J Clin Oncol, 2009, 27(15s): 3509.
  • 4SHIOTA M, FUJIMOTO J, SEMBA T, et al. Hyperphosphorylation of a novel 80 kDa protein- tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3 [J]. Oncogene, 1994, 9(6): 1567-1574.
  • 5MORRIS S W, NAEVE C, MATHEW P, et al. AI_K, the chromosome 2 gene focus altered by the t(2; 5)in non- Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)[J]. Oncogene, 1997, 14(18): 2175-2188.
  • 6EICHENMULLER B, EVERLEY P, PALANGE J, et al. The human EMAP-like protein-70 (ELP70) is a microtubule destabilize that localizes to the mitotic apparatus[J]. J Biol Chem, 2002, 277(2): 1301-1309.
  • 7INAMURA K, TAKEUCHI K, TOGASHI Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset[J]. Mod Pathol, 2009, 22(4): 508-515.
  • 8SHAW A T, YEAP B Y, MINO-KENUDSON M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J].J C/in Oncol, 2009 27(26): 4247-4253.
  • 9ZHANG X, ZHANG S, YANG X, et al. Fusion of EMI4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression[J]. Mol Cancer, 2010, 9: 188.
  • 10Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer[ J ]. Nature,2007,448 (7153) :561 - 566.

共引文献26

同被引文献97

  • 1陆舜.晚期非小细胞肺癌患者个体化治疗的新突破[J].上海交通大学学报（医学版）,2011,31(3):261-264. 被引量：4
  • 2Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [J]. CA Cancer J Clin, 2015,65 ( 1 ) : 5-29. DOI : 10. 3322/eaac. 21254.
  • 3DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014[J]. CA Cancer J Clin, 2014, 64(4) :252-271. DOI: 10. 3322/caac. 21235.
  • 4Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer[J]. J Thorae Dis, 2013,5(Suppl 5 ) : $463-478. DOI: 10. 3978/j. issn. 2072- 1439. 2013.08.43.
  • 5Ozkaya S, Findik S, Dirican A, et al. Long-term survival rates of patients with stage ⅢB and Ⅳ non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine[J]. Exp Ther Med, 2012,4(6) :1035-1038.
  • 6Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis[J]. Lancet Oncol, 2011,12(11) : 1004-1012. DOI: 10. 1016/$1470-2045 (11) 70232-7.
  • 7Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c- MET) kinase and anaplastic lymphoma kinase (ALK) [J]. J Med Chem, 2011, 54 (18): 6342-6363. DOI: 10. 1021/ jm2007613.
  • 8Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 [DB/OL]. The Cochrane Collaboration, 2011 (2011-03), http://www. cochrane-handhook, org.
  • 9Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer [J]. N Engl J Med, 2013, 368 (25): 2385-2394. DOI: 10. 1056/ NEJMoa1214886.
  • 10Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371 (23): 2167-2177. DOI: 10. 1056/ NEJMoa1408440.

引证文献10

二级引证文献35

南方医科大学学报
2015年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部